EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus

Chinyere Aloke iD, Oluwasola Abayomi Adelusi, Olalekan Olugbenga Onisuru, Emmanuel Amarachi Iwuchukwu, Ikechukwu Achilonu

Pharmacoepidemiology and Drug Safety · 2025-12 · 34 (12)

DOI: 10.1002/pds.70277 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 08.12.2025. Verfasst von Chinyere Aloke und 4 weiteren Autor:innen. Beteiligte Einrichtung: Protein Structure-Function and Research Unit, School of Molecular and Cell Biology, Faculty of Science, University of the Witwatersrand, Johannesburg…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Hypoglycemic Agents. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 182 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation (NRF) of South Africa, National Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mounting evidence indicates that Type 2 diabetes mellitus (T2DM) is a public health challenge globally, and its occurrence is anticipated to surge in the forthcoming years. Dipeptidyl peptidase‐4 (DPP‐4) serves as a target for its treatment, with its inhibitors effectively preserving the levels of glucose‐dependent insulinotropic peptide and glucagon‐like peptide 1(GLP‐1). This review presents an overview of the therapeutic possibilities of six frequently employed DPP‐4 inhibitors (DPP‐4is) (Sitagliptin, saxagliptin, vildagliptin, linagliptin, alogliptin and teneligliptin) in managing T2DM, focussing on their characteristics, mechanism of action, advantages and side effects in comparison with alternative oral antidiabetic drugs as well as the possibility of using in silico method in advancing its timely and cost‐effective production.

Methods

A literature search was conducted using the major search engines such as PubMed/Medline, Scopus, and Google Scholar, etc. employing terms like ‘Type 2 diabetes mellitus (T2DM), DPP‐4 inhibitors, and Dipeptidyl peptidase‐4’, etc. to identify relevant studies.

Results

Our findings indicate that DPP‐4is stimulate secretion of insulin and suppress secretion of glucagon by elevating endogenous GLP‐1 concentrations without an intrinsic hypoglycaemia risk. Although these agents share a common mechanism of action, their considerable structural heterogeneity may lead to distinct pharmacological characteristics. Literature shows that DPP‐4is have a promising safety profile in comparison with other oral antidiabetic medications, however, certain safety aspects require additional exploration. Different DPP‐4is have demonstrated comparable safety and tolerability, whether used alone or in combination with other antidiabetic medications. Besides, it has been shown that in silico method could be employed in development of DPP‐4is. Further research is necessary to ascertain whether differences among DPP‐4 inhibitors might influence the occurrence of specific adverse effects.

Conclusion

DPP‐4 inhibitors remain effective and well‐tolerated options for managing T2DM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsHumansGlucagon-Like Peptide 1Dipeptidyl Peptidase 4

Stichwörter der Autor:innen

diabetes mellitusdipeptidyl peptidase‐4glucagon‐like peptide 1glucoseinsulinsitagliptin

Substanzen

Dipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsGlucagon-Like Peptide 1Dipeptidyl Peptidase 4

Autor:innen und Institutionen

  • Protein Structure-Function and Research Unit, School of Molecular and Cell Biology, Faculty of Science, University of the Witwatersrand, Johannesburg, South Africa.
  • Department of Medical Biochemistry, Alex Ekwueme Federal University Ndufu-Alike, Abakaliki, Nigeria.
  • Biotechnology and Food Department, University of Johannesburg, Johannesburg, South Africa.

ORCID-Profile: Chinyere Aloke

Förderung

  • National Research Foundation (NRF) of South Africa
  • National Research Foundation

Zitieren

APA

Aloke, C., Adelusi, O. A., Onisuru, O. O., Iwuchukwu, E. A., & Achilonu, I. (2025). Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus. Pharmacoepidemiology and Drug Safety, 34(12). https://doi.org/10.1002/pds.70277

Vancouver

Aloke C, Adelusi OA, Onisuru OO, Iwuchukwu EA, Achilonu I. Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus. Pharmacoepidemiology and Drug Safety. 2025;34(12). doi:10.1002/pds.70277

BibTeX
@article{Aloke2025,
  author = {Aloke, Chinyere and Adelusi, Oluwasola Abayomi and Onisuru, Olalekan Olugbenga and Iwuchukwu, Emmanuel Amarachi and Achilonu, Ikechukwu},
  title = {Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2025},
  volume = {34},
  number = {12},
  doi = {10.1002/pds.70277}
}
Kostenlos starten →